Features of bone metastases from different tumors
<i>Materials and methods. </i>Monitoring and analysis of features of bone metastases clinical progress in 304 patients with breast, renal, colorectal and non-small cell lung cancer. <i>Results. </i>The research showed that bone metastases most frequently appear during the first clinical relapse (89-96% of all patients with bone metastases) with the exception of colorectal cancer (54%). Relation between bone metastases progress and disease stage has not been revealed. Metastatic spread varied from disseminated (breast cancer) to moderate (lung cancer) and minimal (renal and colorectal cancer). From 17% (colorectal cancer) to 38% (breast cancer) of patients had pathological bone fractures at the moment of bone metastasis identification. Pain syndrome, requiring treatment with narcotics, was strongest for patients with renal cancer (49,5%) and minimal for patients with breast cancer (5,4%). Possibility of dose decrease or recall of analgetics was highest for patients with breast cancer (77%) and lowest for patients with renal cancer (45,5%) and lung cancer (26,4%). Surgical interventions were done to cope with neurological disorders, clinical pain syndrome and as a radical treatment of the disease. Neurological disorders required surgical intervention mostly for patients with renal cancer (11,1%) and colorectal cancer (7,3%), while surgery for pain syndrome was most frequent for patients with renal cancer (9,1%). 21,1% of patients with renal cancer were operated to cure solitary bone metastases. <i>Resume. </i>Modern therapy of bone metastases helps to preserve satisfactory quality of life for the majority of patients. The role of bisphosphonates in bone metastases treatment (with the exception of breast cancer) is still not clearly defined.